Comparing two MRI contrast agents for liver imaging
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether a newer contrast agent, gadopiclenol, works as well as the standard one for liver scans. It might be an option if you need an MRI to check for liver disease, tumors, or treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a liver condition or need an MRI to look at liver spots or tumor follow-up.
- You do not have severe kidney problems (GFR less than 30).
- You are not pregnant and have no allergy to gadolinium contrast agents.
- You can have an MRI (no pacemaker, no severe claustrophobia, etc.).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two contrasting dyes (gadopiclenol and gadobutrol) used during pituitary MRI scans to see which one provides clearer images. It is for adults with known or suspected pituitary lesions that disrupt the blood-brain barrier.
This trial studies an MRI technique using a contrast dye (gadopetate/gadolinium) to better look at liver lesions that may be colon cancer spread. It may help doctors more accurately assess which liver tumors are present and guide next steps.
This trial compares two types of MRI scans to see if one is as good as the other for finding and tracking liver tumors in people with colorectal cancer. You can join if you are starting chemotherapy or need your cancer checked.
This study tests a new contrast agent (a dye injected before an MRI) to see how well it works for people having brain or spinal cord scans. It aims to improve image quality so doctors can see lesions more clearly, which may help with diagnosis and treatment planning.
This trial tests whether a new PET imaging agent (GPC3-targeted) can find liver cancer as well as or better than enhanced MRI. It may help diagnose hepatocellular carcinoma (the most common type of liver cancer) more accurately.
This study tests different MRI imaging techniques to improve how scans look and measure targets. You may be able to join with or without a contrast dye, and you’ll need to travel to the NIH for follow-up visits.
Hear when a new Liver Lesion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.